Cooper Companies ( (COO) ) has released its Q2 earnings. Here is a breakdown of the information Cooper Companies presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CooperCompanies, a prominent player in the global medical device industry, specializes in contact lenses and women’s healthcare products through its CooperVision and CooperSurgical divisions. In its latest earnings report for the second quarter of 2025, CooperCompanies reported a 6% year-over-year increase in revenue, reaching $1,002.3 million. The company’s non-GAAP diluted earnings per share rose by 14% to $0.96, reflecting strong performance in its daily silicone hydrogel and surgical portfolios. Key financial metrics showed an improvement in gross and operating margins, with the latter increasing to 18% from 17% in the previous year. CooperVision’s revenue grew by 5%, while CooperSurgical saw an 8% rise, driven by robust sales in office and surgical products. Looking ahead, CooperCompanies remains focused on expanding its market share and launching new products, with a positive outlook for the remainder of the fiscal year.